Abstract:
The tertiary alcohol a-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy- 1-methylethyl)benzenepropanol, the (aS)-enantioner of which is an intermediate in the production of montelukast, is produced by reacting the novel lactone of formula (II) with a methylmagnesium halide in an ethereal solvent in the presence of lanthanum trichloride and lithium chloride. The lactone II can be prepared by reacting a corresponding hydroxyester with a Grignard reagent in the absence of a lanthanoid compound or with a strong base.
Abstract:
The present invention relates to a method for preparing Montelukast acid or its sodium salt by reacting a thiol compound with a Montelukast intermediate in the presence of a base in a medium comprising an ionic liquid compound. In accordance with the inventive method, highly pure Montelukast acid or its sodium salt, which is advantageously used as a raw material in the preparation of Montelukast, a leukotriene antagonist, can be easily prepared in a high yield.
Abstract:
The tertiary alcohol α-[3-[(1 E )-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy- 1-methylethyl)benzenepropanol, the (α S )-enantioner of which is an intermediate in the production of montelukast, is produced by reacting the novel lactone of formula (II) with a methylmagnesium halide in an ethereal solvent in the presence of lanthanum trichloride and lithium chloride. The lactone II can be prepared by reacting a corresponding hydroxyester with a Grignard reagent in the absence of a lanthanoid compound or with a strong base.
Abstract:
The present application describes deuterium-enriched montelukast, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract:
The invention relates to a novel process for the preparation of Sodium salt of 1- (((l(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(l-hydroxy-l- methylethyl)phenyl) propyl)sulfanyl)methyl)cyclopropaneacetic acid wherein the crystalline forms of methanesulfonate and Montelukast are not isolated. Furthermore, the invention relates to a novel process for preparing salt of 1-(((1(R)- (3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(l-hydroxy-l- methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid with tert- butylamine and the method for its purification to achieve pharmaceutical purity.
Abstract:
Optically active ethenylphenyl-alcohols of formula (I) or its mirror image, wherein R 1 is unsubstituted or substituted heteroaryl and R 2 is phenyl or substituted aryl, are prepared by asymmetric hydrogenation of the corresponding ketones applying hydrogen gas in the presence of specific platinum metal complex catalysts.
Abstract:
A method of preparation of Montelukast of formula (I) by reaction of the compound of formula (III) and a compound of formula (IX), characterized in that the reaction is carried out in the presence of a base, an inert solvent and a component increasing selectivity of the process, especially of a polyether of general formula (XIII), wherein R stands for hydrogen or an alkyl and the value of n varies from 1 to 40, polyethyleneglycol of general formula (XIV), wherein n=l to 40 or a crown-ether of formulae (XV), (XVI) or (XVII).